1. Long‐term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions. (13th December 2013) Authors: Spertino, J.; López‐Ferrer, A.; Vilarrasa, E.; Puig, L. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 28:Number 11(2014:Nov.) Page Start: 1514 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Omalizumab for the treatment of chronic inducible urticaria in 80 patients. (1st January 2021) Authors: Exposito‐Serrano, V.; Curto‐Barredo, L.; Aguilera Peiro, P.; Gómez Armayones, S.; Serra‐Baldrich, E.; Spertino, J.; Bonfill Ortí, M.; Figueras Nart, I.; Melé‐Ninot, G.; Baliu‐Piqué, C.; Sala Cunill, A.; Labrador‐Horrillo, M.; Guilabert Vidal, A.; Fernández Chico, N.; Giménez‐Arnau, A.M. Journal: British journal of dermatology Issue: Volume 184:Number 1(2021) Page Start: 167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Omalizumab for the treatment of chronic inducible urticaria in 80 patients. (2nd September 2020) Authors: Exposito‐Serrano, V.; Curto‐Barredo, L.; Aguilera Peiro, P.; Gómez Armayones, S.; Serra‐Baldrich, E.; Spertino, J.; Bonfill Ortí, M.; Figueras Nart, I.; Melé‐Ninot, G.; Baliu‐Piqué, C.; Sala Cunill, A.; Labrador‐Horrillo, M.; Guilabert Vidal, A.; Fernández Chico, N.; Giménez‐Arnau, A.M. Journal: British journal of dermatology Issue: Volume 184:Number 1(2021) Page Start: 167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria. (1st July 2018) Authors: Curto‐Barredo, L.; Spertino, J.; Figueras‐Nart, I.; Expósito‐Serrano, V.; Guilabert, A.; Melé‐Ninot, G.; Cubiró, X.; Bonfill‐Ortí, M.; Garcias‐Ladaria, J.; Villar, M.; García‐Navarro, X.; Bielsa‐Marsol, I.; Vilavella, M.; Aparicio, G.; Baliu‐Piqué, C.; Álvarez, A.; Lamas‐Domenech, N.; Duran‐Jordà... Journal: British journal of dermatology Issue: Volume 179:Number 1(2018) Page Start: 210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria. (25th April 2018) Authors: Curto‐Barredo, L.; Spertino, J.; Figueras‐Nart, I.; Expósito‐Serrano, V.; Guilabert, A.; Melé‐Ninot, G.; Cubiró, X.; Bonfill‐Ortí, M.; Garcias‐Ladaria, J.; Villar, M.; García‐Navarro, X.; Bielsa‐Marsol, I.; Vilavella, M.; Aparicio, G.; Baliu‐Piqué, C.; Álvarez, A.; Lamas‐Domenech, N.; Duran‐Jordà... Journal: British journal of dermatology Issue: Volume 179:Number 1(2018) Page Start: 210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Wells syndrome and chronic spontaneous urticaria: report of four cases successfully treated with omalizumab. (3rd June 2019) Authors: Ogueta, I.; Spertino, J.; Deza, G.; Alcantara Luna, S.; Zaragoza Ninet, V.; Pujol, R.M.; Giménez‐Arnau, A.M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 33:Number 10(2019) Page Start: e388 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗